IOPtima holds a U.S. Patent on the basic concept of the technology that it has developed for the treatment of glaucoma and submitted applications for patent applications in other countries click to see full text . Bio – IOPtima is a subsidiary of Bio-Light Life Science Investments, a management and holding company specializing in biomedical technologies. BOLT: Bio – Light the Tel Aviv Stock the Tel Aviv Stock Exchange under the symbol TASE.
The marketIt is estimated that nearly 67 million people worldwide suffer from glaucoma. Glaucoma is a chronic disease that requires life-long therapy. Drug treatments in the amount of $ 2-3 billion spent globally each year, often because of the low patient compliance has not, and because it is in many cases limited long-term effectiveness. Early surgical intervention is performed sometimes more effective than surgery after many years of drug therapy.
As the registrational trial began, more than 1,900 ,, safety and efficacy of the technological in recognizing cervical cancer, to one arm of the trial assess the efficacy an experimental commercial versions of the device and one-way The disposable. The study protocol compiles specify states that all subjects were designated after passing of Pap, or had another risk factor fulfills the referral criteria of this study -. Each subject was Light Touch LightTouch investigational product apparatus and underwent an additional pap smear screening, colposcopic testing and biopsy. Two generations of of the investigational medicinal Light Touch in this study in the study.